AnaptysBio authorizes $50M stock repurchase plan; cash >$575M

ANAPTYSBIO, INC

Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.
Cash, equivalents, and investments >$575M as of Dec 31, 2022.
Reiterates ~4 years of capital to execute R&D plan, excluding potential GSK royalties.
Repurchases may occur in open market under Rule 10b5-1 and 10b-18; no obligation to buy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.